Best Healthcare Companies in Melbourne, Australia
The 155 best Healthcare companies in Melbourne, Australia in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Mesoblast.
Ranked: Best Healthcare companies in Melbourne
| # | Company | Last round | Disclosed funding | Employees | Founded | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 11:11 Granola Breakfast cereals brand | — | — | — | 2013 | Rob Rabba Founder | — | — | — |
| 2 | 360biolabs Contract service company specializing in virology and immunology services | — | — | 78 | 2015 | — | WordPressMySQLPHP+19 | — | 1 partnership |
| 3 | A Sashi Vitamins Provider of hydroponic systems and gardening supplies | — | — | — | 2012 | James Christian Founder | — | — | — |
| 4 | Abano Healthcare Operator of a network providing support services to dental practices | — | — | 2,500 | 1999 | — | BugHerdGoogle MapsMicrosoft ASP.NET+30 | — | — |
| 5 | Absolute Health & Performance Provider of private personal training and allied health services | — | — | — | 2016 | David Smith Co-Founder | — | — | — |
| 6 | ACLabs Laboratory focused on providing cannabis testing services | — | — | — | 2016 | — | — | — | — |
| 7 | Acrux Drug development company focused on commercialising topical products using its proprietary drug delivery… | — | — | 83 | 1998 | — | WordPressMySQLPHP+17 | — | 3 partnerships |
| 8 | advent health group Advent Health Group is a health care center that offers physiotherapy, osteopathy, and podiatry services. | — | — | 30 | 2019 | — | — | — | — |
Top 12 Healthcare companies in Melbourne
#1
Public · Melbourne, Victoria · founded 2012 · 141 employees$114.8Mraised▾
Manufacturer of respiratory imaging and ventilation analysis equipment
- Jan 2026Post IPO$100.5M
- Jul 2023Grant (prize money)$740K
- May 2023Post IPO$13.6M
#2
Public · Melbourne, Victoria · founded 2004 · 83 employees$979.8Mraised▾
Mesoblast specializes in developing cellular medicines. The company has a clinically advanced and diverse portfolio of cell-based products with five programs, two of which are partnered, in active Phase 3 clinical studies or Phase 3-ready, and four programs in Phase 2. These clinical programs target therapeutic areas including cardiac diseases, spine orthopedic disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions. The Japanese Government has approved TEMCELL® HS. Inj., a product based on their proprietary allogeneic mesenchymal lineage adult stem cell technology licensed to JCR Pharmaceuticals Co. Ltd for the treatment of graft versus host disease in children and adults in Japan. Their product candidate, MSC-100-IV, has orphan drug designation and is being developed under an accelerated regulatory approval pathway in line with the United States Food and Drug Administration (FDA) discussions for children with steroid-refractory acute graft versus host disease. Two other lead product candidates, MPC-150-IM and MPC-06-ID, are in late-stage development in Phase 3 programs targeting, respectively, advanced chronic heart failure and chronic low bac
- Jan 2025Post IPO$160M
- Apr 2023Post IPO—
- Aug 2022Post IPO$45M
- Mar 2021Post IPO$110M
#3
Public · Melbourne, Victoria · founded 2021 · 18 employees$3Mraised▾
Provider of phase I & II clinical trial services for mental health diseases
- Apr 2026Post IPO$987.9K
- May 2025Post IPO$66.6K
- Apr 2025Post IPO$1.4M
- Apr 2025Post IPO$111.7K
#4
Series B · Melbourne, Victoria · founded 2019$15Mraised▾
Developer of an AI assistant designed for clinical documentation support. The AI transcribes visits, structures notes, and generates referrals. It also auto-applies codes and tasks, and sends information to electronic health records. The AI adapts to various clinical specialties and settings.
- Oct 2025Series B$65M
- Mar 2025Series A$16.6M
- Oct 2023Series A$10M
- Aug 2021Seed$5M
#5
Seed · Melbourne, Victoria · founded 2023 · 12 employees$24.3Mraised▾
Foundation focused on providing of accessible healthcare services
- Sep 2024Seed$13.5M
- Mar 2024Seed$8.2M
- May 2023Seed$2.7M
#6
Acquired · Melbourne, Victoria · founded 2003$667Mraised▾
Healthcare organization focused on improving the quality of healthcare services
#7
Series B · Melbourne, Victoria · founded 2020 · 11 employees$32.1Mraised▾
R&D company manufacturing drugs for multiple therapeutic areas
- May 2023Series B$15M
- Feb 2022Series B$17.1M
#8
Series A · Melbourne, Victoria · founded 2021 · 19 employees$5Mraised▾
Neo-Bionica is a collaborative initiative between the Bionics Institute and The University of Melbourne, located in St Vincent's Hospital, Melbourne. They specialize in developing medical device prototypes for targeted therapies and diagnostics.
- May 2024Series A$5M
#9
Public · Melbourne, Victoria · founded 2014$70.7Mraised▾
Paradigm Biopharma focussed on repurposing pentosan polysulphate sodium (PPS) for new orthopaedic and respiratory applications. Its lead clinical indications include treating injuries that result in bone marrow edema (BME) and the allergic inflammatory response in allergic rhinitis (AR), which is commonly known as ‘Hay Fever’. Its PPS formulations in development include Zilosul for patients with a BME lesion following an ACL injury (Phase 2); Rhinosul nasal spray for Allergic Rhinitis (Phase 1). The company also has a preclinical program for allergic asthma.
- Apr 2020Post IPO$21.6M
- Apr 2019Post IPO$36.9M
- Dec 2018Post IPO—
- Oct 2018Post IPO$6.4M
#10
Series B · Melbourne, Victoria · founded 2017 · 31 employees$7Mraised▾
Atmo Biosciences is a spinoff of the RMIT University in Melbourne, Australia that is commercializing a swallowable gas sensor that can reliably profile and monitor intestinal gases such as hydrogen, carbon dioxide, oxygen, etc. in real time. The capsule seamlessly transmits the data to a smartphone. Atmo has partnered with Planet Innovation, a product development firm, to develop their technology as a diagnostic device for an array of gut disorders, from food nutrient malabsorption to colon cancer.
- Sep 2023Series B—
- Mar 2023Series B$5.3M
- Jun 2020Seed$1.7M
- Mar 2019Seed—
#11
Acquired · Melbourne, Victoria · founded 1990 · 201 employees$58.2Mraised▾
Chain of eye care hospitals
- Jul 2015Post IPO$26.7M
- Oct 2014Post IPO$10M
- Nov 2012Post IPO$21.5M
#12
Seed · Melbourne, Victoria · founded 2023$750Kraised▾
Kite Therapy is an early childhood transdisciplinary therapy program that focuses on developing children's communication, social, motor, and emotional resilience skills at home. They offer services for families of children with autism and developmental delays aged 1-6, utilizing NDIS plans for support.
- May 2024Seed$750K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Healthcare coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.